oscarglendwgn的部落格

心肌梗塞來的突然，置放血管支架是救命選項之一。過去血管支架是以裸金屬支架及塗藥支架為主，當裸金屬支架置入後，血管被撐開，支架貼於血管內面，血管中內皮細胞會自然癒合結痂，但癒合過程卻因結疤過厚而容易再度狹窄。

振興醫院心臟內科主任、台灣介入性心臟血管醫學會理事長殷偉賢表示，塗藥支架就是塗了一層抑制細胞增長的藥，在傷口癒合的過程，的確有效地減少再狹窄率，但同時傷口癒合期也拉長，造成金屬長時間暴露在血液裡，增加引起血栓的風險，嚴重的會導致心肌梗塞再次發生，所以必須長期服用抗血小板藥物來降低血栓風險。但有些病人服藥配合度不高，擅自停藥；有些病人因為近期要手術，不得不提早停藥，都會導致支架治療效果及安全性無法同時兼顧。

救心救命新武器 心臟支架科技重大突破！

根據日前於巴黎舉行的歐洲心血管介入治療大會(Euro PCR)發表的突破性研究，內容為長達18個月追蹤1500位心肌梗塞病患，在使用生物活性支架後明顯大幅降低心肌梗塞再發生及心臟病死亡的風險，相對安全性提高，且服用抗血小板藥物時間也能大幅縮短，同時兼顧支架治療效果及安全性。

殷偉賢主任說明，現在新一代生物活性塗層支架上的塗層，能夠促進傷口提早癒合，再加上支架結構厚度較薄，所以內皮傷口可以很快地復原。新一代生物活性塗層支架的設計就是希望傷口提早癒合，當傷口癒合好了後，就完整的血管內皮層可以隔開金屬支架和血液接觸，就能降低血栓的風險發生，這樣一來同時兼顧了支架的有效性跟安全性。另外殷主任補充，新一代生物活性塗層支架對於有特殊需求的病患，如不按時服藥、不能吃太強效的抗血栓藥物，對藥物過敏或緊急需要手術的病患更是新的突破性治療選擇。

支架選擇考慮這三點 與醫討論再決定

採用支架治療心肌梗塞時，應該考慮病患是否能遵從醫囑長期用藥，能否承受長期服用抗血栓藥物的副作用，或是近期內是否有開刀安排。每個病患合適的支架不同，在治療方式的選擇上，應該與醫師共同討論，視自身情況，再決定出效益最好的治療方式。

Suddenly, the placement of a blood vessel stent is one of the lifesaving options. In the past, the vascular stent was mainly a bare metal stent and an applicator stent. When the bare metal stent was placed, the blood vessel was opened, and the stent was attached to the inner surface of the blood vessel. The endothelial cells in the blood vessel naturally healed and crusted, but the healing process was caused by The knot is too thick and easy to narrow again.

Yin Weixian, director of the Department of Cardiology at the Revitalization Hospital and director of the Taiwan Interventional Cardiovascular Medicine Association, said that the drug-coated stent is coated with a drug that inhibits cell growth. In the process of wound healing, it effectively reduces the rate of restenosis, but at the same time the wound healing period. It is also elongated, causing metal to be exposed to the blood for a long time, increasing the risk of thrombosis, which can lead to recurrence of myocardial infarction. Therefore, antiplatelet drugs must be taken for a long time to reduce the risk of thrombosis. However, some patients do not have a high degree of medication, and they stop taking the drug without authorization. Some patients have to stop the drug because of the recent surgery, which will lead to the treatment effect and safety of the stent.

Save your heart and save your life. A major breakthrough in heart stent technology!

According to a breakthrough study published at the European Conference on Cardiovascular Interventions (Euro PCR) in Paris, the content of 1500 patients with myocardial infarction was tracked for 18 months, significantly reducing the recurrence of myocardial infarction after using bioactive stents. And the risk of death from heart disease, relative safety, and the time to take antiplatelet drugs can be significantly reduced, while taking into account the effectiveness and safety of stent treatment.

Director Yin Weixian explained that the coating on the new generation bioactive coating stent can promote the early healing of the wound, and the thickness of the stent structure is thin, so the endothelial wound can be quickly restored. The design of a new generation of bioactive coated stents is to hope that the wounds will heal early. When the wounds are healed, the intact vascular endothelium can separate the metal stent from the blood, which can reduce the risk of thrombosis. The effectiveness and safety of the stent. In addition, Director Yin added that a new generation of bioactive coated stents for patients with special needs, such as not taking drugs on time, not taking too strong antithrombotic drugs, is more new to patients with drug allergies or urgent need for surgery. Breakthrough treatment options.

The choice of stents considers these three points.

When using a stent to treat myocardial infarction, you should consider whether the patient can follow the long-term medication, whether he can bear the side effects of long-term antithrombotic drugs, or whether there is a planned operation in the near future. Each patient has a different stent. In the choice of treatment method, it should be discussed with the doctor, depending on the situation, and then determine the best treatment.

Laennec is the ethical drug manufactured with JBP’s unique technologies.

Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.